Corcept Therapeutics (CORT) Tops Q3 EPS by 3c
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $79.62 -0.11%
EPS Growth %: -96.6%
Financial Fact:
Net loss and comprehensive loss: 2.59M
Today's EPS Names:
MAYS, CRMT, REPL, More
EPS Growth %: -96.6%
Financial Fact:
Net loss and comprehensive loss: 2.59M
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
Corcept Therapeutics (NASDAQ: CORT) reported Q3 EPS of $0.04, $0.03 better than the analyst estimate of $0.01. Revenue for the quarter came in at $21.7 million versus the consensus estimate of $21.24 million.
GUIDANCE:
Corcept Therapeutics sees Q4 2016 revenue of $79-82 million, versus the consensus of $80.3 million.
For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
- Bernstein SocGen Reiterates Outperform Rating on Fervo Energy (FRVO)
- Ares Management, L.P. (ARES) PT Raised to $153 at TD Cowen
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
